Biotech

Naturally Splendid Appoints Marketing Executive to Advisory Board

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce the addition of Marketing Executive, Drago Adam to their Advisory Board

Drago launched his own marketing company 23 years ago, The Adam Ad Group, after a professional hockey career in the New York Rangers system. Drago has directed all aspects of their client's marketing plans, which include, strategic planning, media buying, creative content development, video and web production, search engine optimization, social and digital marketing, as well as pay per click campaigns.

The Adam Ad Group works across a varied roster of clients including some of the largest automotive dealers and dealer groups in Canada. Drago has earned an exceptional reputation providing online marketing, product review campaigns, content creation and syndication, as well as social and digital media management.

Drago has also created an online newsletter called The Monday Morning Motivator which has a subscriber base of over 119,000 people.

Drago states, "I have been in the advertising and marketing industry for over two decades and have a passion for creating campaigns that are as unique as our clients are. In this case, I am excited to be joining the Advisory team at Naturally Splendid as I have a special interest in the brands and products of the Company especially as a former professional athlete and now a consumer of plant-based foods for over two years. I look forward to providing guidance as Naturally Splendid continues to build their presence in the plant-based market".

Naturally Splendid CEO Mr. J. Craig Goodwin states, "We are excited to have Drago join the Naturally Splendid Advisory Board. Drago's advertising and marketing acumen, in combination with his professional athletic career and plant-based diet, make him a perfect addition as we continue to penetrate the plant-based market. Combining Drago's ability to oversee content creation, with the cooking demonstrations and blogs of Naturally Splendid Advisor and Executive Chef Alastair Gregor (news release February 9, 2021) is just one example of how we can educate consumers on the benefits of a plant-based diet in an informative and fun manner while creating additional attention for the Natera brand. We look forward to working with Drago on many e-commerce and social media initiatives".

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-465-0548 (ext. 105).

On Behalf of the Board of Directors

Mr. J. Craig Goodwin
CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N - Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a Safe Quality Food Level 2 certified food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment.

The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19.

NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of products will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/639116/Naturally-Splendid-Appoints-Marketing-Executive-to-Advisory-Board

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share

BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that the Company has completed the previously-announced strategic investment by Prevail Partners, LLC (" Prevail Partners ") in the Company (the " Investment "), in accordance with a stock purchase agreement (the " Agreement ") entered into between the Company and Prevail Partners on May 12, 2023. Pursuant to the Agreement, the Company issued 463,408 common shares (the " Shares ") to Prevail Partners (the " Issuance ") at a price per Share of US$8.63 for aggregate gross proceeds of US$4 million.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Boosh Hires Pixie Brands and Multi Brands Sampling Co for BC Promos and Store Sampling

Boosh Hires Pixie Brands and Multi Brands Sampling Co for BC Promos and Store Sampling

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company"), a premier plant-based brand in the "better for you" food sector, announced today it is working with Pixie Brands @meetpixiebrands and Multi Brand Sampling Co @multibrandsmaplingco to promote and enhance sales at store level for all Boosh and Beanfields brands in BC.

Founded by CPG founder April Angelini, Pixie Brands offers a relationship-based, boots on the ground approach to help small and medium brands SHINE. They offer sales and distributor support and organize In-Store Events.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS

Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission's (FTC) complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc:

"Amgen is disappointed by the FTC's decision and remains committed to completing this acquisition, which will bring significant benefits to patients suffering from very serious rare diseases in the U.S. and around the world.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

  • Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP.
  • Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for BriaCell's upcoming pivotal study, expected to commence in 2023.

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the Company has signed a Master Service and Technology Agreement ("MSTA") agreement with Prevail InfoWorks, Inc. ("InfoWorks"), a Philadelphia, PA based Contract Research Organization (CRO), to provide clinical services and technologies for BriaCell's upcoming pivotal study in advanced metastatic breast cancer. Services include clinical site coordination, project management, clinical monitoring and pharmacovigilance (safety management) services, and the use of InfoWork's integrated real-time data analytics platform, The Single Interface ® for clinical support and real-time data analysis.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
  Sirona Biochem Chief Scientific Officer Géraldine Deliencourt-Godefroy

Sirona Biochem Eyes Licensing Deal for Anti-aging Compound After Clinical Trial Results

Sirona Biochem (TSXV:SBM) is looking forward to securing a licensing deal after a clinical trial for its novel anti-aging compound TFC-1326 showed exceptional results, according to Géraldine Deliencourt-Godefroy, the company’s chief scientific officer.

“We have ongoing discussions with different partners that have shown interest in this compound … we have an event in Boston where we (will) share with other prospects (the) best results in order to find a way to license this compound,” Deliencourt-Godefroy said.

The clinical trial was conducted among 20 volunteers who used the compound in cream form two times a day for three months.

Keep reading...Show less
Sirona Biochem: Investing News Network Interview with CSO, Dr. Geraldine Deliencourt-Godefroy

Sirona Biochem: Investing News Network Interview with CSO, Dr. Geraldine Deliencourt-Godefroy

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that the Investing News Network has published an exclusive video interview with Dr. Geraldine Deliencourt-Godefroy, the Chief Scientific Officer of Sirona.

In the interview, Dr. Deliencourt-Godefroy shares the remarkable story behind her groundbreaking discovery in anti-aging, TFC-1326, and discusses the recent clinical trial that showed exceptional results in aging skin without any adverse side effects.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×